Jacobio, a Beijing Pharma, Out-Licenses Two SHP2 Candidates to AbbVie

Jacobio Pharma of Beijing out-licensed rights for its two-molecule SHP2 program to AbbVie. SHP inhibitors, which target a key node in cancer and immune cells, are expected to reduce cancer growth in several cancer types while they also increase immune responses. Although AbbVie will own exclusive rights to the SHP2 portfolio, Jacobio will conduct early global clinical trials of the molecules, with AbbVie paying R&D expenses. AbbVie will be responsible for global R&D though Jacobio has an option to develop the SHP2 program in greater China. More details.... Stock Symbol: (NYSE: ABBV) Share this with colleagues: // //